BIO is committed to enhancing patient lives through the discovery, development, and delivery of treatments. To understand the needs of patients, we collaborate closely with patient organizations and caregivers. Patient Advocacy & Alliances serves as a bridge between BIO and third-party stakeholders, identifying mutual interests and fostering meaningful partnerships. We host regular educational programs and capacity-building initiatives, offering opportunities for stakeholder organizations to actively participate in BIO conferences and events. Join us in making a difference in patients.
Sign-up to join BIOAction, BIO's grassroots advocacy program. You will be notified about relevant policy issues where we need you to contact your lawmaker.
A two-day event to discuss timely policy issues and share best practices.
Patient Advocacy Pavilion fosters partnerships between biopharma and nonprofits, advancing innovative therapies to cure and prevent disease, enhancing patient lives.
We’ve made it easier for you to access information and share content about biotechnology and prescription medicines.
Access educational and advocacy recordings.
BIO and its members share a commitment to discovering and developing innovative medicines to fight and cure disease and improve the lives of patients. In an effort to achieve our shared goals of bringing new treatments to patients, BIO and its members often work together with patient advocacy organizations to better understand the patients we serve, to help raise awareness and understanding of a disease, and to advance patient-focused public policies. To ensure that these collaborations respect the independence of all partners and are built on integrity and trust, BIO developed a set of guiding principles which reflect these values to help inform interactions between BIO members and the patient advocacy community. Click below to view the BIO's Guiding Principles for Interaction with Patient Advocacy Organizations.
7,000+ rare diseases, 30 new annually. Termed orphan diseases, they impact <200K patients in the U.S. each.
AMR kills 25K/year in the U.S. & 700K globally. By 2050, fatalities may hit 10M. A critical public health threat with no new antibiotics in 40 years.
Explore the latest updates, advocacy efforts, and policy initiatives championed by the Biotechnology Innovation Organization.
BIO is proud to partner with stakeholder organizations to help advance our shared goal of bringing new treatments to patients with serious medical conditions and to support public policies that promote innovation and improve patient access.